Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Histiocytosis, Langerhans-Cell | 14 | 2025 | 241 | 3.630 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 7 | 2024 | 149 | 1.060 |
Why?
|
| Proto-Oncogene Proteins B-raf | 5 | 2025 | 222 | 0.950 |
Why?
|
| Xanthogranuloma, Juvenile | 2 | 2022 | 34 | 0.890 |
Why?
|
| Histiocytosis, Sinus | 1 | 2022 | 34 | 0.760 |
Why?
|
| Benzimidazoles | 1 | 2022 | 129 | 0.700 |
Why?
|
| Histiocytosis | 1 | 2020 | 19 | 0.660 |
Why?
|
| Pneumothorax | 1 | 2020 | 83 | 0.620 |
Why?
|
| Hodgkin Disease | 2 | 2019 | 305 | 0.600 |
Why?
|
| Telomere Shortening | 1 | 2019 | 34 | 0.600 |
Why?
|
| Telomerase | 1 | 2019 | 168 | 0.570 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 137 | 0.550 |
Why?
|
| Rituximab | 1 | 2018 | 166 | 0.550 |
Why?
|
| Neutropenia | 1 | 2019 | 205 | 0.540 |
Why?
|
| Glioma | 1 | 2022 | 534 | 0.530 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2016 | 5 | 0.510 |
Why?
|
| Lung Diseases | 1 | 2020 | 409 | 0.490 |
Why?
|
| Mutation | 4 | 2019 | 6250 | 0.490 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 897 | 0.460 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2016 | 158 | 0.440 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 410 | 0.440 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2022 | 200 | 0.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 1348 | 0.390 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2025 | 356 | 0.380 |
Why?
|
| Histiocytes | 2 | 2022 | 25 | 0.330 |
Why?
|
| Infant | 14 | 2025 | 13198 | 0.330 |
Why?
|
| Adolescent | 17 | 2025 | 20560 | 0.330 |
Why?
|
| Child, Preschool | 14 | 2025 | 14862 | 0.320 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2024 | 608 | 0.300 |
Why?
|
| Child | 18 | 2025 | 25835 | 0.300 |
Why?
|
| Neurodegenerative Diseases | 2 | 2025 | 281 | 0.300 |
Why?
|
| Fever of Unknown Origin | 2 | 2018 | 45 | 0.290 |
Why?
|
| Humans | 32 | 2025 | 132373 | 0.250 |
Why?
|
| Young Adult | 8 | 2025 | 9949 | 0.220 |
Why?
|
| Signal Transduction | 2 | 2017 | 4725 | 0.220 |
Why?
|
| Genes, Neurofibromatosis 2 | 1 | 2004 | 4 | 0.220 |
Why?
|
| MAP Kinase Signaling System | 2 | 2024 | 309 | 0.220 |
Why?
|
| Remission Induction | 2 | 2023 | 307 | 0.220 |
Why?
|
| Arthritis, Juvenile | 1 | 2024 | 42 | 0.220 |
Why?
|
| Rheumatic Diseases | 1 | 2024 | 73 | 0.210 |
Why?
|
| Adult | 14 | 2025 | 31624 | 0.210 |
Why?
|
| Interferon-gamma | 2 | 2022 | 539 | 0.200 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 569 | 0.200 |
Why?
|
| Cytarabine | 1 | 2023 | 102 | 0.200 |
Why?
|
| Meningioma | 1 | 2004 | 140 | 0.190 |
Why?
|
| Male | 19 | 2025 | 65072 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 92 | 0.180 |
Why?
|
| Meningeal Neoplasms | 1 | 2004 | 215 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 947 | 0.180 |
Why?
|
| Brain Neoplasms | 2 | 2018 | 1409 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 1038 | 0.180 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 175 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2004 | 634 | 0.170 |
Why?
|
| Female | 18 | 2025 | 70809 | 0.170 |
Why?
|
| Pleurodesis | 1 | 2020 | 15 | 0.170 |
Why?
|
| Chest Tubes | 1 | 2020 | 37 | 0.170 |
Why?
|
| Thiotepa | 1 | 2020 | 14 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 558 | 0.160 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2021 | 225 | 0.160 |
Why?
|
| Sepsis | 2 | 2021 | 518 | 0.160 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 103 | 0.150 |
Why?
|
| Blood Cells | 1 | 2019 | 56 | 0.150 |
Why?
|
| Etanercept | 1 | 2018 | 47 | 0.150 |
Why?
|
| Janus Kinases | 1 | 2018 | 32 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 449 | 0.140 |
Why?
|
| Transplantation Conditioning | 1 | 2020 | 300 | 0.140 |
Why?
|
| Graft Rejection | 2 | 2018 | 560 | 0.140 |
Why?
|
| STAT1 Transcription Factor | 1 | 2018 | 76 | 0.140 |
Why?
|
| Osteopontin | 1 | 2018 | 51 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 503 | 0.140 |
Why?
|
| Smad6 Protein | 1 | 2017 | 8 | 0.140 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 672 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 109 | 0.130 |
Why?
|
| STAT3 Transcription Factor | 1 | 2018 | 232 | 0.120 |
Why?
|
| Databases, Genetic | 1 | 2019 | 500 | 0.120 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2018 | 217 | 0.120 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2016 | 66 | 0.120 |
Why?
|
| Clonal Evolution | 1 | 2016 | 50 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 667 | 0.120 |
Why?
|
| Hydroxyurea | 1 | 2016 | 85 | 0.120 |
Why?
|
| Lymph Nodes | 1 | 2017 | 388 | 0.120 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 368 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 169 | 0.110 |
Why?
|
| Genetic Testing | 2 | 2021 | 1098 | 0.110 |
Why?
|
| Treatment Outcome | 8 | 2024 | 13020 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2016 | 436 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 1192 | 0.110 |
Why?
|
| Infant, Newborn | 4 | 2020 | 8574 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 2 | 2018 | 903 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2004 | 1541 | 0.110 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 1831 | 0.100 |
Why?
|
| Exome | 1 | 2016 | 1086 | 0.090 |
Why?
|
| Genome, Human | 1 | 2018 | 1332 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3853 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 759 | 0.090 |
Why?
|
| Cardiac Output | 1 | 2011 | 166 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 3088 | 0.080 |
Why?
|
| Biopsy | 3 | 2018 | 1289 | 0.080 |
Why?
|
| Recurrence | 2 | 2024 | 1458 | 0.080 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 1964 | 0.080 |
Why?
|
| Prognosis | 1 | 2019 | 5010 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1881 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 380 | 0.070 |
Why?
|
| Mycophenolic Acid | 2 | 2018 | 57 | 0.070 |
Why?
|
| Oxygen | 1 | 2011 | 572 | 0.070 |
Why?
|
| Anemia | 1 | 2011 | 351 | 0.070 |
Why?
|
| Bone Marrow | 2 | 2018 | 332 | 0.070 |
Why?
|
| Middle Aged | 4 | 2025 | 28895 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 3358 | 0.060 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2024 | 3 | 0.060 |
Why?
|
| Paresis | 1 | 2004 | 33 | 0.050 |
Why?
|
| Adenine Nucleotides | 1 | 2024 | 36 | 0.050 |
Why?
|
| Arabinonucleosides | 1 | 2024 | 33 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2025 | 364 | 0.050 |
Why?
|
| Clone Cells | 1 | 2004 | 179 | 0.050 |
Why?
|
| Epilepsies, Partial | 1 | 2004 | 95 | 0.050 |
Why?
|
| Spinal Neoplasms | 1 | 2004 | 74 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2024 | 201 | 0.050 |
Why?
|
| Renal Dialysis | 2 | 2018 | 889 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 2004 | 348 | 0.040 |
Why?
|
| Exons | 1 | 2004 | 803 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 2004 | 482 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 501 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 234 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 184 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 182 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 17371 | 0.040 |
Why?
|
| Mannose-Binding Lectins | 1 | 2020 | 26 | 0.040 |
Why?
|
| Antigens, CD1 | 1 | 2020 | 23 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 198 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2017 | 3422 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2020 | 73 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 278 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2019 | 65 | 0.040 |
Why?
|
| Biomarkers | 2 | 2020 | 3391 | 0.040 |
Why?
|
| Drug Eruptions | 1 | 2019 | 33 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2020 | 118 | 0.040 |
Why?
|
| Antigens, Fungal | 1 | 2018 | 34 | 0.040 |
Why?
|
| Histoplasma | 1 | 2018 | 37 | 0.040 |
Why?
|
| Liver Failure | 1 | 2019 | 91 | 0.040 |
Why?
|
| Amphotericin B | 1 | 2018 | 91 | 0.040 |
Why?
|
| Histoplasmosis | 1 | 2018 | 55 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 249 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 675 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2019 | 121 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2020 | 437 | 0.030 |
Why?
|
| Nitriles | 1 | 2018 | 156 | 0.030 |
Why?
|
| Age of Onset | 1 | 2019 | 626 | 0.030 |
Why?
|
| Gain of Function Mutation | 1 | 2018 | 111 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 856 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2020 | 377 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 263 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 308 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2017 | 87 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 167 | 0.030 |
Why?
|
| Pyrroles | 1 | 2018 | 183 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2020 | 448 | 0.030 |
Why?
|
| Viral Load | 1 | 2018 | 410 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 1 | 2018 | 225 | 0.030 |
Why?
|
| Piperidines | 1 | 2018 | 236 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 185 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2018 | 330 | 0.030 |
Why?
|
| United States | 2 | 2024 | 11631 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 248 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 565 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2018 | 326 | 0.030 |
Why?
|
| Fetal Diseases | 1 | 2019 | 463 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2018 | 419 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1153 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 956 | 0.030 |
Why?
|
| Family | 1 | 2017 | 595 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 554 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2018 | 822 | 0.020 |
Why?
|
| Aged | 2 | 2024 | 21386 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 4767 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 3062 | 0.020 |
Why?
|
| Survival Rate | 1 | 2016 | 2187 | 0.020 |
Why?
|
| Lactates | 1 | 2011 | 101 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2011 | 194 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 4695 | 0.020 |
Why?
|
| Oximetry | 1 | 2011 | 179 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2011 | 322 | 0.020 |
Why?
|
| Phenotype | 1 | 2019 | 4545 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2011 | 295 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 5153 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 2851 | 0.020 |
Why?
|
| Texas | 1 | 2016 | 3629 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2557 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 3200 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2011 | 1373 | 0.010 |
Why?
|
| Neoplasms | 1 | 2019 | 2949 | 0.010 |
Why?
|
| Mice | 1 | 2021 | 18572 | 0.010 |
Why?
|
| Risk Factors | 1 | 2016 | 10912 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 6457 | 0.010 |
Why?
|
| Animals | 1 | 2021 | 34996 | 0.010 |
Why?
|